Teclistamab (JNJ-64007957) is an anti-CD3/B-cell maturation antigen (BCMA) Duobody currently in phase 2 testing in r/r multiple myeloma (MM) (NCT04557098) [91,92], as is also Talquetamab (JNJ-64407564), an anti-GPRC5D/CD3 DuoBody (NCT04634552). This evidence concerns the gene TNFRSF17 and AL amyloidosis.